Nicolás Cuba Cáceres, MD

As Nicolas approached the end of medical school, he set his sights on a career in psychiatry, with a particular focus on OCD. He immersed himself in the literature on these topics and eventually secured a position at Harvard Medical School's Neuromodulation Lab at Spaulding Hospital in Boston. His time in this lab enabled him to deepen his understanding of neuroscience and clinical research methodologies. But he came to realize that his true passion was work more directly on treatment development.

Recognizing the worldwide need for new effective treatments for the 30-40% of OCD sufferers who do not respond to available treatments, Nicolas committed himself full time to developing a promising discovery. In November 2022, Nicolas reached out to Dr. Christopher Pittenger, a world expert in the development of novel treatments for OCD, for mentorship. Their partnership evolved into Alco Therapeutics.